VISTAGEN THERAPEUTICS INC (VTGN) Fundamental Analysis & Valuation

NASDAQ:VTGN • US92840H4002

0.6077 USD
-0.01 (-1.07%)
At close: Mar 6, 2026
0.6183 USD
+0.01 (+1.74%)
After Hours: 3/6/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This VTGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Overall VTGN gets a fundamental rating of 2 out of 10. We evaluated VTGN against 520 industry peers in the Biotechnology industry. VTGN may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, VTGN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. VTGN Profitability Analysis

1.1 Basic Checks

  • VTGN had negative earnings in the past year.
  • In the past year VTGN has reported a negative cash flow from operations.
  • VTGN had negative earnings in each of the past 5 years.
  • In the past 5 years VTGN always reported negative operating cash flow.
VTGN Yearly Net Income VS EBIT VS OCF VS FCFVTGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M -50M

1.2 Ratios

  • The Return On Assets of VTGN (-79.04%) is worse than 66.54% of its industry peers.
  • VTGN's Return On Equity of -100.98% is in line compared to the rest of the industry. VTGN outperforms 44.62% of its industry peers.
Industry RankSector Rank
ROA -79.04%
ROE -100.98%
ROIC N/A
ROA(3y)-121.84%
ROA(5y)-93.98%
ROE(3y)-196.14%
ROE(5y)-141.94%
ROIC(3y)N/A
ROIC(5y)N/A
VTGN Yearly ROA, ROE, ROICVTGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VTGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VTGN Yearly Profit, Operating, Gross MarginsVTGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10K -10K 20K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. VTGN Health Analysis

2.1 Basic Checks

  • VTGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for VTGN has been increased compared to 1 year ago.
  • VTGN has more shares outstanding than it did 5 years ago.
  • VTGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VTGN Yearly Shares OutstandingVTGN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
VTGN Yearly Total Debt VS Total AssetsVTGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • VTGN has an Altman-Z score of -10.81. This is a bad value and indicates that VTGN is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -10.81, VTGN is not doing good in the industry: 73.46% of the companies in the same industry are doing better.
  • VTGN has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • VTGN has a Debt to Equity ratio (0.01) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -10.81
ROIC/WACCN/A
WACC8.79%
VTGN Yearly LT Debt VS Equity VS FCFVTGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 4.67 indicates that VTGN has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 4.67, VTGN is in line with its industry, outperforming 54.04% of the companies in the same industry.
  • A Quick Ratio of 4.67 indicates that VTGN has no problem at all paying its short term obligations.
  • VTGN's Quick ratio of 4.67 is in line compared to the rest of the industry. VTGN outperforms 55.38% of its industry peers.
Industry RankSector Rank
Current Ratio 4.67
Quick Ratio 4.67
VTGN Yearly Current Assets VS Current LiabilitesVTGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. VTGN Growth Analysis

3.1 Past

  • The earnings per share for VTGN have decreased strongly by -27.84% in the last year.
  • Looking at the last year, VTGN shows a very negative growth in Revenue. The Revenue has decreased by -54.32% in the last year.
  • Measured over the past years, VTGN shows a very negative growth in Revenue. The Revenue has been decreasing by -24.07% on average per year.
EPS 1Y (TTM)-27.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.17%
Revenue 1Y (TTM)-54.32%
Revenue growth 3Y-24.07%
Revenue growth 5YN/A
Sales Q2Q%29.49%

3.2 Future

  • The Earnings Per Share is expected to grow by 26.29% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, VTGN will show a very strong growth in Revenue. The Revenue will grow by 235.72% on average per year.
EPS Next Y-15.13%
EPS Next 2Y11.2%
EPS Next 3Y15.98%
EPS Next 5Y26.29%
Revenue Next Year30.08%
Revenue Next 2Y111.5%
Revenue Next 3Y359.07%
Revenue Next 5Y235.72%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VTGN Yearly Revenue VS EstimatesVTGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 200M 400M 600M 800M 1B
VTGN Yearly EPS VS EstimatesVTGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -200 -400 -600

More info and screens

Find the best growth stocksShow best growing peers

0

4. VTGN Valuation Analysis

4.1 Price/Earnings Ratio

  • VTGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VTGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VTGN Price Earnings VS Forward Price EarningsVTGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VTGN Per share dataVTGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

  • VTGN's earnings are expected to grow with 15.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.2%
EPS Next 3Y15.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VTGN Dividend Analysis

5.1 Amount

  • No dividends for VTGN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VTGN Fundamentals: All Metrics, Ratios and Statistics

VISTAGEN THERAPEUTICS INC

NASDAQ:VTGN (3/6/2026, 8:00:02 PM)

After market: 0.6183 +0.01 (+1.74%)

0.6077

-0.01 (-1.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)06-15
Inst Owners25.84%
Inst Owner Change-40.9%
Ins Owners0.2%
Ins Owner Change1.64%
Market Cap24.08M
Revenue(TTM)486.00K
Net Income(TTM)-51.42M
Analysts50
Price Target3.8 (525.31%)
Short Float %4.43%
Short Ratio0.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1%
Min EPS beat(2)-11.22%
Max EPS beat(2)9.22%
EPS beat(4)3
Avg EPS beat(4)3.84%
Min EPS beat(4)-11.22%
Max EPS beat(4)14.73%
EPS beat(8)6
Avg EPS beat(8)8.63%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-7.44%
Min Revenue beat(2)-18.84%
Max Revenue beat(2)3.95%
Revenue beat(4)1
Avg Revenue beat(4)-43.35%
Min Revenue beat(4)-95.33%
Max Revenue beat(4)3.95%
Revenue beat(8)2
Avg Revenue beat(8)-30.36%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-74.31%
EPS NQ rev (1m)11.4%
EPS NQ rev (3m)2.41%
EPS NY rev (1m)0%
EPS NY rev (3m)-15.8%
Revenue NQ rev (1m)-16.18%
Revenue NQ rev (3m)-23.52%
Revenue NY rev (1m)3.59%
Revenue NY rev (3m)77.69%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 49.39
P/FCF N/A
P/OCF N/A
P/B 0.47
P/tB 0.47
EV/EBITDA N/A
EPS(TTM)-1.89
EYN/A
EPS(NY)-1.27
Fwd EYN/A
FCF(TTM)-1.53
FCFYN/A
OCF(TTM)-1.53
OCFYN/A
SpS0.01
BVpS1.29
TBVpS1.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.04%
ROE -100.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.84%
ROA(5y)-93.98%
ROE(3y)-196.14%
ROE(5y)-141.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 127.81%
Cap/Sales 49.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.67
Quick Ratio 4.67
Altman-Z -10.81
F-Score1
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)112.3%
Cap/Depr(5y)140.71%
Cap/Sales(3y)45.45%
Cap/Sales(5y)36.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.17%
EPS Next Y-15.13%
EPS Next 2Y11.2%
EPS Next 3Y15.98%
EPS Next 5Y26.29%
Revenue 1Y (TTM)-54.32%
Revenue growth 3Y-24.07%
Revenue growth 5YN/A
Sales Q2Q%29.49%
Revenue Next Year30.08%
Revenue Next 2Y111.5%
Revenue Next 3Y359.07%
Revenue Next 5Y235.72%
EBIT growth 1Y-69.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-131.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-131.06%
OCF growth 3YN/A
OCF growth 5YN/A

VISTAGEN THERAPEUTICS INC / VTGN FAQ

What is the fundamental rating for VTGN stock?

ChartMill assigns a fundamental rating of 2 / 10 to VTGN.


What is the valuation status for VTGN stock?

ChartMill assigns a valuation rating of 0 / 10 to VISTAGEN THERAPEUTICS INC (VTGN). This can be considered as Overvalued.


Can you provide the profitability details for VISTAGEN THERAPEUTICS INC?

VISTAGEN THERAPEUTICS INC (VTGN) has a profitability rating of 0 / 10.


What is the financial health of VISTAGEN THERAPEUTICS INC (VTGN) stock?

The financial health rating of VISTAGEN THERAPEUTICS INC (VTGN) is 3 / 10.


Can you provide the expected EPS growth for VTGN stock?

The Earnings per Share (EPS) of VISTAGEN THERAPEUTICS INC (VTGN) is expected to decline by -15.13% in the next year.